5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Elevated Serum Ceruloplasmin Levels Are Associated with Higher Impulsivity in People with Parkinson's Disease

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Heightened impulsivity has been reported in a subset of people with Parkinson's disease (PwP) and is considered a risk factor for the development of impulse control disorders (ICDs). However, at present, there are no recognised biochemical markers of heightened impulsivity.

          Objectives

          To determine if ceruloplasmin, a serum marker involved in the regulation of iron and copper homeostasis, is associated with trait impulsivity in PwP.

          Methods

          The study measured serum ceruloplasmin and impulsivity using the Barratt Impulsiveness Scale (BIS-11) in an Australian cohort of 214 PwP. Multivariate general linear models (GLMs) were used to identify whether higher serum ceruloplasmin levels (>75th percentile) were significantly predictive of BIS-11 scores.

          Results

          Serum ceruloplasmin was higher in females with PD ( p < 0.001) and associated with MDS-UPDRS III, Hoehn and Yahr, and ACE-R scores ( p < 0.05). When correcting for covariates, higher serum ceruloplasmin concentrations were associated with the 2 nd order nonplanning impulsivity and with the 1st order self-control and cognitive complexity impulsivity domains.

          Conclusions

          Higher serum ceruloplasmin levels are independently associated with heightened nonplanning impulsivity in PwP. Thus, serum ceruloplasmin levels may have clinical utility as a marker for heightened impulsivity in PD.

          Related collections

          Most cited references 43

          • Record: found
          • Abstract: found
          • Article: not found

          The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening.

          There is a clear need for brief, but sensitive and specific, cognitive screening instruments as evidenced by the popularity of the Addenbrooke's Cognitive Examination (ACE). We aimed to validate an improved revision (the ACE-R) which incorporates five sub-domain scores (orientation/attention, memory, verbal fluency, language and visuo-spatial). Standard tests for evaluating dementia screening tests were applied. A total of 241 subjects participated in this study (Alzheimer's disease=67, frontotemporal dementia=55, dementia of Lewy Bodies=20; mild cognitive impairment-MCI=36; controls=63). Reliability of the ACE-R was very good (alpha coefficient=0.8). Correlation with the Clinical Dementia Scale was significant (r=-0.321, p<0.001). Two cut-offs were defined (88: sensitivity=0.94, specificity=0.89; 82: sensitivity=0.84, specificity=1.0). Likelihood ratios of dementia were generated for scores between 88 and 82: at a cut-off of 82 the likelihood of dementia is 100:1. A comparison of individual age and education matched groups of MCI, AD and controls placed the MCI group performance between controls and AD and revealed MCI patients to be impaired in areas other than memory (attention/orientation, verbal fluency and language). The ACE-R accomplishes standards of a valid dementia screening test, sensitive to early cognitive dysfunction. Copyright (c) 2006 John Wiley & Sons, Ltd.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls.

            Fifty-six heroin addicts and 60 age-matched controls were offered choices between monetary rewards ($11-$80) available immediately and larger rewards ($25-$85) available after delays ranging from 1 week to 6 months. Participants had a 1-in-6 chance of winning a reward that they chose on one randomly selected trial. Delay-discounting rates were estimated from the pattern of participants' choices. The discounting model of impulsiveness (Ainslie, 1975) implies that delay-discounting rates are positively correlated with impulsiveness. On average, heroin addicts' discount rates were twice those of controls (p = .004), and discount rates were positively correlated with impulsivity as measured by self-report questionnaires (p < .05). The results lend external validity to the delay-discounting rate as a measure of impulsiveness, a characteristic associated with substance abuse.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Fifty years of the Barratt Impulsiveness Scale: An update and review

                Bookmark

                Author and article information

                Contributors
                Journal
                Parkinsons Dis
                Parkinsons Dis
                PD
                Parkinson's Disease
                Hindawi
                2090-8083
                2042-0080
                2020
                30 September 2020
                : 2020
                Affiliations
                1Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, Australia
                2Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Nedlands, Western Australia, Australia
                3School of Health Sciences, University of Notre Dame Australia, Fremantle, Western Australia, Australia
                4Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria 3010, Australia
                5Centre for Clinical Neurosciences and Neurological Research, St. Vincent's Hospital Melbourne, Fitzroy, Victoria 3065, Australia
                6Institute for Health Research, University of Notre Dame Australia, Fremantle, Western Australia, Australia
                7Centre for Molecular Medicine & Innovative Therapeutics, Murdoch University, Perth, Western Australia, Australia
                Author notes

                Academic Editor: Carlo Ferrarese

                Article
                10.1155/2020/8296203
                7545407
                Copyright © 2020 Megan C. Bakeberg et al.

                This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                Funding
                Funded by: Federal Cooperative Research Centre for Mental Health
                Funded by: Perron Institute for Neurological and Translational Science
                Funded by: University of Notre Dame Australia
                Categories
                Research Article

                Neurology

                Comments

                Comment on this article